Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Opposite long-term regulation of c-Myc and p27Kip1 through overactivation of Raf-1 and the MEK/ERK module in proliferating human choroidal melanoma cells

Oncogene volume 22, pages 8813–8822 (2003)Cite this article

Abstract

Although there is no current evidence for ras gene mutation in choroidal melanoma, there is an increasing body of evidence indicating that deregulated intracellular signalling pathways are involved in choroidal melanoma pathogenesis. The various components of the linear Raf/MEK/ERK signalling pathway have been implicated in various tumours. We therefore investigated the role of Raf-1 and the MEK/ERK module in the proliferation of human normal choroidal melanocytes (NCM) and cells from the ocular choroidal melanoma (OCM-1) cell line. OCM-1 cells proliferated four times faster than NCM. High basal activation of the MEK/ERK module was observed in unstimulated OCM-1 cells, whereas rapid and persistent activation was detected after serum stimulation, throughout the 24-h period of culture. In contrast, the activation of MEK/ERK was barely detectable in unstimulated NCM and occurred late (6 h) after the stimulation of cell proliferation. Inhibition of Raf-1 and MEK1/2 activation by pharmacological approaches and of the production of Raf-1 and ERK1/2 by antisense oligonucleotide approaches demonstrated that Raf-1 and the MEK/ERK module controlled proliferation in OCM-1 cells, but not in NCM. OCM-1 cells produced very low levels of p27Kip1, whereas NCM produced constant, high levels of p27Kip1. The inhibition of Raf-1 or MEK1/2 induced a large increase in p27Kip1 in OCM-1 cells, associated with an arrest of cell proliferation. Levels of c-Myc production were high and constant in OCM-1 cells and low in NCM, in contrast to what was observed for p27Kip1. The inhibition of both Raf-1 and MEK1/2 induced a decrease in c-Myc production and downregulated c-Myc activity by preventing c-Myc phosphorylation in OCM-1 cells. We conclude that Raf-1 and the MEK/ERK module control the production of both p27Kip1 and c-Myc, and the activation of c-Myc for OCM-1 cell proliferation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Alessi DR, Cuenda A, Cohen P, Dudley DT and Saltiel AR . (1995). J. Biol. Chem., 270, 27489–27494.

  • Barry OP, Mullan B, Sheehan D, Kazanietz MG, Shanahan F, Collins JK and O'Sullivan GC . (2001). J. Biol. Chem., 276, 15537–15546.

  • Casagrande F, Bacqueville D, Pillaire MJ, Malecaze F, Manenti S, Breton-Douillon M and Darbon JM . (1998). FEBS Lett., 422, 385–390.

  • Chang L and Karin M . (2001). Nature, 410, 37–40.

  • Chuang CF and Ng SY . (1994). FEBS Lett., 346, 229–234.

  • Coats S, Flanagan WM, Nourse J and Roberts JM . (1996). Science, 272, 877–880.

  • D'Agnano I, Valentini A, Fornari C, Bucci B, Starace G, Felsani A and Citro G . (2001). Oncogene, 20, 2814–2825.

  • Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA . (2002). Nature, 417, 949–954.

  • Gille H and Downward J . (1999). J. Biol. Chem., 274, 22033–22040.

  • Guise S, Braguer D, Carles G, Delacourte A and Briand C . (2001). J. Neurosci. Res., 63, 257–267.

  • Gupta S, Seth A and Davis RJ . (1993). Proc. Natl. Acad. Sci. USA, 90, 3216–3220.

  • Her JH, Wu J, Rail TB, Sturgill TW and Weber MJ . (1991). Nucleic Acids Res., 19, 3743.

  • Hoshino R, Tanimura S, Watanabe K, Kataoka T and Kohno M . (2001). J. Biol. Chem., 276, 2686–2692.

  • Hu DN, McCormick SA, Ritch R and Pelton-Henrion K . (1993). Invest. Ophthalmol. Vis. Sci., 34, 2210–2219.

  • Jamerson M, Johnson M and Dickson RB . (2000). Oncogene, 19, 1065–1071.

  • Kan-Mitchell J, Mitchell MS, Rao N and Liggett PE . (1989). Invest. Ophthalmol. Vis. Sci., 30, 829–834.

  • Kimura A, Ohmichi M, Kurachi H, Ikegami H, Hayakawa J, Tasaka K, Kanda Y, Nishio Y, Jikihara H, Matsuura N and Murata Y . (1999). Cancer Res., 59, 5133–5142.

  • Krueger JS, Keshamouni VG, Atanaskova N and Reddy KB . (2001). Oncogene, 20, 4209–4218.

  • Marshall CJ and Leevers SJ . (1995). Methods Enzymol., 255, 273–279.

  • Monia BP, Johnston JF, Geiger T, Muller M and Fabbro D . (1996). Nat. Med., 2, 668–675.

  • Mooy CM, Van der Helm MJ, Van der Kwast TH, De Jong PT, Ruiter DJ and Zwarthoff EC . (1991). Br. J. Cancer., 64, 411–413.

  • Mosmann TJ . (1983). Immunol. Methods., 65, 55–63.

  • Mouriaux F, Casagrande F, Pillaire MJ, Manenti S, Malecaze F and Darbon JM . (1998). Invest. Ophthalmol. Vis. Sci., 39, 876–884.

  • Mouriaux F, Maurage CA, Labalette P, Sablonniere B, Malecaze F and Darbon JM . (2000). Invest. Ophthalmol. Vis. Sci., 41, 2837–2843.

  • Pages G, Guerin S, Graill D, Bonino F, Smith A, Anjuere F, Auberger P and Pouyssegur J . (1999). Science, 286, 1374–1377.

  • Parrella P, Caballero OL, Sidransky D and Merbs SL . (2001). Invest. Ophthalmol. Vis. Sci., 42, 1679–1684.

  • Peyssonnaux C, Provot S, Felder-Schmittbuhl MP, Calothy G and Eychene A. (2000). Mol. Cell. Biol., 20, 7068–7079.

  • Pyrhonen S . (1998). Invest. Ophthalmol. Vis. Sci., 34 (Suppl 3), S27–30.

  • Sivaraman VS, Wang H, Nuovo GJ and Malbon CC . (1997). J. Clin. Invest., 99, 1478–1483.

  • Soparker CN, O'Brien JM and Albert DM . (1993). Invest. Ophthalmol. Vis. Sci., 34, 2203–2209.

  • Volmat V and Pouyssegur J . (2001). Biol. Cell, 93, 71–79.

  • Wang L, Liu F and Adamo M . (2001). J. Biol. Chem., 40, 37242–37249.

  • Weinstein-Oppenheimer CR, Blalock WL, Steelman LS, Chang F and McCubrey JA . (2000). Pharmacol. Ther., 88, 229–279.

  • Wilkinson MG and Millar JB . (2000). FASEB J., 14, 2147–2157.

Download references

Acknowledgements

This study was supported by grants (4474) from Association pour la Recherche sur le Cancer (ARC), (R03/75-03) from Ligue contre le cancer, (00-5-12641) from Ministere de la Recherche and Association Française des Amblyopes Unilatéraux (AFAU).

Author information

Authors and Affiliations

  1. INSERM U450, Institut Biomédical des Cordeliers, IFR58, 15, rue de l'Ecole de Médecine, Paris, 75006, France

    Gaëlle Lefevre, Armelle Calipel, Frédéric Mouriaux, Christiane Hecquet & Frédéric Mascarelli

  2. Service d'Ophtalmologie, Hopital Purpan, CHRU, Toulouse, 31000, France

    François Malecaze

Authors
  1. Gaëlle Lefevre
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Armelle Calipel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frédéric Mouriaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christiane Hecquet
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. François Malecaze
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Frédéric Mascarelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frédéric Mascarelli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lefevre, G., Calipel, A., Mouriaux, F. et al. Opposite long-term regulation of c-Myc and p27Kip1 through overactivation of Raf-1 and the MEK/ERK module in proliferating human choroidal melanoma cells. Oncogene 22, 8813–8822 (2003). https://doi.org/10.1038/sj.onc.1207099

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207099

Keywords

This article is cited by

Search

Advanced search

Quick links